genae Opens Offices in London

ANTWERP, Belgium and LONDON --

genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the incorporation of genae UK in London.

The United Kingdom has one of the largest medical device markets in the world. It was valued at USD 8.9 billion in 2012 and it is projected to increase by a CAGR of 6.0% until 2017. Health expenditure was estimated at USD 234 billion in 2012, equal to 9.5% of GDP. Despite recessionary pressures, market growth rates over the coming years will be positive.

"The mature and high value medical device market in Western Europe is wealthy and developed. The friction between attempts to contain health costs and a desire to remain at the forefront of technological innovation leads to an increased demand for efficiencies. For example: medical devices that facilitate minimally invasive therapies to ensure a faster turnaround of patients." said Bart Segers, CEO at genae. "The incorporation of genae UK is a logical step in our commitment to provide high quality research services on a global scale."

London is a leading global city with many strengths that contribute to its prominence. It is one of the world's leading financial centers and its universities form the largest concentration of higher education in Europe. London has a diverse range of people and cultures and has one of the largest city airport and transportation systems, measured by passenger traffic.

About genae

genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice.

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for clinical trial management, data management, statistical analysis, safety, regulatory, core laboratory and medical writing services for the medical industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium and is part of the genae group, the medical device CRO.

To learn more about genae, please visit http://www.genae.com.

Contact
genae associates nv
Bart Segers, CEO
+32-3-290-03-06
[email protected]

 

genae UK Limited
20-22 Bedford Row
London WC1R 4JS, UK

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Signant Health is ramping up its virtual trial model after buying VirTrial to “truly digitize the operations of clinical study sites.”

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.